Dana-Farber Cancer Institute

Why trials sponsored by Dana-Farber Cancer Institute stopped, in this sample of ClinicalTrials.gov.

16 stopped trials with a clear reason; 81% ended for non-scientific reasons.

Where it ranks

• #1 of 88 sponsors by share of trials stopped for: safety (19%).

Among ranked sponsors in this sample. Shares of stopped trials, not failure rates. See all scorecards.

Trials

• UNTIRE: Cancer-related Fatigue With Digital Treatment
  NCT05584540 · WITHDRAWN · funding or business
  “loss of funding”
• Axillary Lymph Node Tattoo Marking Study
  NCT04947917 · TERMINATED · funding or business
  “Institutional standard of care regarding axillary management changed. Decision was made to close the study early.”
• Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions
  NCT04071756 · TERMINATED · slow enrollment
  “Difficulty with patient recruitment”
• Avelumab and Radiation in Muscle-Invasive Bladder Cancer
  NCT03747419 · TERMINATED · slow enrollment
  “In agreement with the drug sponsor and the institution, the trial has been terminated due to slow accrual.”
• A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer
  NCT03131206 · TERMINATED · slow enrollment
  “Study closed due to slow accrual and lack of efficacy.”
• Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
  NCT02439138 · TERMINATED · safety
  “Safety issues from trials in CLL”
• Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors
  NCT02452710 · TERMINATED · funding or business
  “Study funding was completed.”
• Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)
  NCT01799135 · TERMINATED · slow enrollment
  “Slow accrual”
• Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma
  NCT01484314 · TERMINATED · slow enrollment
  “Low accrual.”
• Dasatinib in Advanced Squamous Cell Lung Cancer
  NCT01491633 · TERMINATED · safety
  “Safety issues/concerns per DF/HCC PI”
• Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
  NCT01222572 · TERMINATED · slow enrollment
  “Slow accrual due to restrictive eligibility criteria”
• Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
  NCT00910000 · TERMINATED · safety
  “Terminated due to unacceptable toxicity”
• Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery
  NCT00458549 · TERMINATED · slow enrollment
  “Slow Accrual”
• rhEndostatin Protein Involving Pediatric Patients With Cancer
  NCT00165373 · TERMINATED · drug or device supply
  “Lack of drug supply”
• Treatment of Childhood Acute Lymphoblastic Leukemia
  NCT00165087 · TERMINATED · regulatory or ethics
  “Terminated by IRB for continuing review”
• GO-203-2C + Bortezomib For Relapsed Or Refractory MM
  NCT02658396 · WITHDRAWN · funding or business
  “Study was never open due to lack of funding”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.